Korea Investment CORP Boosts Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

• Korea Investment CORP increased its stake in Intuitive Surgical, Inc. by 4.4% during Q1, owning approximately 315,299 shares valued at $156.2 million.
• Intuitive Surgical reported $2.19 earnings per share for the last quarter, exceeding estimates and showing a 21.4% year-over-year revenue increase to $2.44 billion.
• Analysts have mixed ratings on Intuitive Surgical, with the stock receiving fourteen buy ratings, one sell rating, and a consensus target price of $595.95.

Korea Investment CORP raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 4.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 315,299 shares of the medical equipment provider's stock after purchasing an additional 13,388 shares during the quarter. Korea Investment CORP owned about 0.09% of Intuitive Surgical worth $156,158,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ISRG. Nuveen LLC purchased a new position in Intuitive Surgical during the first quarter valued at $1,715,899,000. GAMMA Investing LLC increased its position in shares of Intuitive Surgical by 54,010.7% during the first quarter. GAMMA Investing LLC now owns 3,028,576 shares of the medical equipment provider's stock valued at $14,999,630,000 after acquiring an additional 3,022,979 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Intuitive Surgical by 26.1% during the first quarter. Goldman Sachs Group Inc. now owns 2,819,666 shares of the medical equipment provider's stock valued at $1,396,496,000 after acquiring an additional 584,375 shares during the last quarter. Northern Trust Corp increased its position in shares of Intuitive Surgical by 15.8% during the fourth quarter. Northern Trust Corp now owns 3,619,293 shares of the medical equipment provider's stock valued at $1,889,126,000 after acquiring an additional 494,496 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Intuitive Surgical by 1.4% in the first quarter. Vanguard Group Inc. now owns 32,665,531 shares of the medical equipment provider's stock valued at $16,178,258,000 after purchasing an additional 453,335 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Insider Activity at Intuitive Surgical

In other news, EVP Myriam Curet sold 4,500 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the sale, the executive vice president directly owned 353 shares of the company's stock, valued at $173,845.44. The trade was a 92.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mark Brosius sold 216 shares of the stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president directly owned 907 shares in the company, valued at approximately $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,839 shares of company stock worth $7,896,972. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Trading Up 0.7%

Shares of ISRG opened at $480.26 on Monday. The company has a market cap of $172.16 billion, a price-to-earnings ratio of 66.98, a P/E/G ratio of 5.03 and a beta of 1.59. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00. The business's fifty day simple moving average is $508.75 and its two-hundred day simple moving average is $524.77.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The firm had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. During the same quarter last year, the business posted $1.78 earnings per share. The firm's revenue was up 21.4% on a year-over-year basis. As a group, research analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Citigroup reiterated a "buy" rating and issued a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft cut shares of Intuitive Surgical from a "hold" rating to a "sell" rating and cut their target price for the company from $515.00 to $440.00 in a report on Monday, June 9th. Royal Bank Of Canada boosted their price objective on shares of Intuitive Surgical from $605.00 to $615.00 and gave the company an "outperform" rating in a research note on Wednesday, July 23rd. Robert W. Baird dropped their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Finally, Truist Financial upped their price target on shares of Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $595.95.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.